Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
General15 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News14 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
General23 hours agoDe Minaur to face Djokovic at Wimbledon, as Kasatkina bows out in straight sets
-
General17 hours agoBack-to-back rate cuts tipped when Reserve Bank meets